Flamel Technologies (FLML +3.2%) says that a U.S. District Court has dismissed a class action suit against the company, and its former CEO. The initial class action, filed in 2007, alleged that the company made false claims about Coreg CR, a medication commonly used to treat conditions related to the heart and blood vessels. In dismissing the case, the judge stated that there was no substantive fact, and no reasonable jury could possibly find in the lead plaintiff's favor.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs